Trevor A. Mullin

Associate

Trevor Mullin is a business law associate based in Foley & Lardner LLP’s Los Angeles office. He is a member of the Transactions Practice Group and supports clients in equity and debt financings, mergers and acquisitions, corporate formations and governance, and securities law compliance. Trevor has counseled a broad range of clients, including investment funds, startup businesses, nonprofits, and public companies.

Throughout his career, Trevor’s previous experience has provided him meaningful insights in addressing the unique needs of clients in the technology, energy, and life science industries. He enjoys working with companies and investors spearheading efforts for innovation, whether that be in the development of AI, sustainability solutions, or clean energy efforts, among others.

Trevor is a graduate of the UCLA School of Law, where he specialized in business law. During law school, Trevor started his career at Foley as a summer associate. Prior to his time at Foley, he served as a legal fellow at the Williams Institute, an LGBTQ+ focused law and policy think tank. Before law school, Trevor began his legal career as a corporate and securities paralegal for a global law firm in the San Francisco Bay Area.

 

13 February 2024 Deals and Wins

Foley Represents TCGX as Lead Investor in $127.5M Private Placement for Adverum Biotechnologies

Foley & Larder LLP represented TCG Crossover as the lead investor in the $127.5 million private placement for Adverum Biotechnologies.
13 February 2024 Deals and Wins

Foley Represents TCGX as Investor in $120M Private Placement for Silence Therapeutics

Foley & Larder LLP represented TCG Crossover (“TCGX”) as an investor in the $120 million private placement for Silence Therapeutics.
13 February 2024 Deals and Wins

Foley Represents TCGX as Lead Investor in $120M Private Financing for Mineralys Therapeutics

Foley & Larder LLP recently represented TCG Crossover as a lead investor in the $120 million private financing for Mineralys Therapeutics.
24 January 2024 Deals and Wins

Foley Represents TCGX as Investor in Tourmaline Bio, Concurrent with Merger with Talaris Therapeutics

Foley & Lardner LLP represented TCGX as an investor in the $75 million private placement for Tourmaline Bio, concurrent with the company’s merger with Talaris Therapeutics.
23 January 2024 Deals and Wins

Foley Represents TCGX as Co-Lead Investor in $150M Series B Financing for Alkeus Pharmaceuticals

Foley & Lardner LLP represented TCGX as co-lead investor in the $150 million Series B financing for Alkeus Pharmaceuticals.
18 January 2024 Deals and Wins

Foley Represents NEA as Lead Investor in Comanche Biopharma Series B Round

Foley & Lardner LLP recently represented New Enterprise Associates, Inc. as lead investor in Comanche Biopharma Corp’s $75 million Series B financing.